The invention relates to compds. of formula I, to processes for their prepn. and uses thereof. Compds. of formula I wherein E is (CH2)1-2; A is O and S; B and D are independently C and CH; Y, Y and Z are independently S, N, O, C and CH; R1-R4 are independently H, Me, Et, absent, etc.; R5 is H, C1-8 alkyl and C5-6 cycloalkyl; R6 is substituted Me and substituted benzyl; and their salts, tautomers, geometric isomers, enantiomers, diastereomers and racemates thereof, are claimed. Example compd. II was prepd. via heterocyclization of Et 4-oxo-3-tetrahydrothiophenecarboxylate with S-Et isothiouronium bromide; the resulting 2-(ethylthio)thieno[3,4-d]pyrimidin-4(3H,5H,7H)-one underwent hydrolysis to give thiono[3,4-d]pyrimidine-2,4(1H,3H,5H,7H)-dione, which underwent N-alkylation with (S)-3-[(tert-butoxycarbonyl)amino]oxetan-2-one to give (S)-1-[2'-(tert-butoxycarbonyl)amino-2'-carboxyethyl]thieno[3,4-d]pyrimidine-2,4-(1H,3H,5H,7H)-dione, which underwent deprotection to give II. All the invention compds. were evaluated for their glutamatergic receptor binding affinity (some data given).

Pyrimidinedione derivatives as AMPA glutamatergic receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of CNS diseases

FATTORUSSO, CATERINA;
2008

Abstract

The invention relates to compds. of formula I, to processes for their prepn. and uses thereof. Compds. of formula I wherein E is (CH2)1-2; A is O and S; B and D are independently C and CH; Y, Y and Z are independently S, N, O, C and CH; R1-R4 are independently H, Me, Et, absent, etc.; R5 is H, C1-8 alkyl and C5-6 cycloalkyl; R6 is substituted Me and substituted benzyl; and their salts, tautomers, geometric isomers, enantiomers, diastereomers and racemates thereof, are claimed. Example compd. II was prepd. via heterocyclization of Et 4-oxo-3-tetrahydrothiophenecarboxylate with S-Et isothiouronium bromide; the resulting 2-(ethylthio)thieno[3,4-d]pyrimidin-4(3H,5H,7H)-one underwent hydrolysis to give thiono[3,4-d]pyrimidine-2,4(1H,3H,5H,7H)-dione, which underwent N-alkylation with (S)-3-[(tert-butoxycarbonyl)amino]oxetan-2-one to give (S)-1-[2'-(tert-butoxycarbonyl)amino-2'-carboxyethyl]thieno[3,4-d]pyrimidine-2,4-(1H,3H,5H,7H)-dione, which underwent deprotection to give II. All the invention compds. were evaluated for their glutamatergic receptor binding affinity (some data given).
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/361685
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact